Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: A meta-analysis

Summary Background:  An increasing number of hypermethylated genes in stool samples have been reported as biomarkers for the detection of colorectal cancer (CRC) or adenomas. We aimed to comprehensively review and compare the evidence for feasibility of using these biomarkers for the detection of co...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical practice (Esher) Vol. 65; no. 12; pp. 1313 - 1320
Main Authors Luo, Y.-X., Chen, D.-K., Song, S.-X., Wang, L., Wang, J.-P.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.12.2011
Wiley-Blackwell
Hindawi Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Background:  An increasing number of hypermethylated genes in stool samples have been reported as biomarkers for the detection of colorectal cancer (CRC) or adenomas. We aimed to comprehensively review and compare the evidence for feasibility of using these biomarkers for the detection of colorectal neoplasia. Methods:  We searched Medline, the Web of Science and OVID for studies that used hypermethylated genes as biomarkers for the detection of CRC or adenomas. A meta‐analysis was carried out using the random‐effect model with diagnostic odd ratios (DOR) and 95% confidence intervals (CI) as effect measurements. Results:  A total of 19 studies including 2,356 patients were eligible for final analysis. The sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and DOR for the detection of CRC or adenomas were 0.62 (95% CI: 0.51–0.71), 0.89 (95% CI: 0.86–0.92), 5.66 (95% CI: 4.68–6.83), 0.43 (95% CI: 0.34–0.55) and 13.15 (95% CI: 9.82–17.60) respectively. Of these, the sensitivity and specificity for the detection of adenoma were 0.54 (95% CI: 0.39–0.68) and 0.88 (95% CI: 0.83–0.92) respectively. Conclusions:  Hypermethylated gene panels are not currently accurate enough to be used alone for colorectal neoplasia screening. The discovery and evaluation of additional biomarkers with improved sensitivity and specificity is necessary. Linked Comment: Stein. Int J Clin Pract 2011; 65: 1212‐3.
Bibliography:ArticleID:IJCP2800
ark:/67375/WNG-K8M9ZZT0-G
istex:290D4C7422B3409D79245E98873ACEC7BD88947F
Grant Support
Disclosures
This work was supported by the Guangdong Provincial Scientific Research Grants (4010251008901000008; L.W.), the National Natural Scientific Foundation of China Grants (81072042; L.W.) and the Yat‐sen Innovative Talents Cultivation Program for Excellent Tutors (88000‐3126200; Y.X.L. and J.P.W.).
Linked Comment
Stein. Int J Clin Pract 2011; 65: 1212‐3
The authors declare no conflicts of interest.
.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Review-3
ISSN:1368-5031
1742-1241
DOI:10.1111/j.1742-1241.2011.02800.x